ALENDRONATE

本子项目是利用由NIH/NCRR资助的中心赠款提供的资源的众多研究子项目之一。子项目和研究者（PI）可能已经从另一个NIH来源获得了主要资金，因此可以在其他CRISP条目中表示。列出的机构是中心的，不一定是研究者的机构。本研究旨在研究骨质流失高危人群的发病机制和治疗方法。前列腺癌是美国男性中最常见的癌症，也是癌症死亡的第二大原因。在过去的十年中，越来越多的男性接受激素抑制疗法治疗局部晚期疾病。最近的研究表明，黄体生成素释放激素（LHRH）类似物的激素抑制会导致骨质快速流失，增加骨质疏松性骨折的风险(1)。老年男性髋部骨折和其他脆性骨折发生率的增加是一个重大的公共卫生问题。髋部骨折代价高昂，死亡率增加，严重影响幸存者的独立性和生活质量。该研究的基本原理是，在局部晚期前列腺癌患者接受激素抑制治疗时，可能会使这一问题复杂化。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This proposal is designed to examine pathogenetic mechanisms and therapy in a population of men at high risk for bone loss. Carcinoma of the prostate gland is the most commonly diagnosed cancer in U.S. men, and is the second leading cause of cancer death. Over the last decade, more and more men are being treated with hormonal suppression therapy for locally advanced disease. Recent studies have shown that such hormonal suppression with Luteinizing Hormone Releasing Hormone (LHRH) analogs leads to rapid bone loss and increased risk of osteoporotic fractures (1). The increased incidence of hip fractures and other fragility fractures in older men is a major public health issue. Hip fractures are costly, increase mortality and significantly compromise the independence and quality of life of the survivors. The potential for compounding this problem in men treated with hormonal suppression for locally advanced prostate carcinoma is the rationale for this study.